The city of Durham, North Carolina, currently has 37 active clinical trials seeking participants for Breast Cancer research studies.
Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer
Recruiting
This is a multi-institutional, single arm, open label, Phase Ib/II study of abemaciclib in combination with elacestrant in patients with HR+/Her2- breast cancer metastatic to the brain. Patients may have received up to two prior lines of systemic chemotherapy for locally advanced or metastatic disease. There will be no limit on prior use of endocrine therapy including aromatase inhibitors, tamoxifen and fulvestrant, given a documented clinical benefit of elacestrant in this setting.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2023
Locations: Duke Cancer Center, Durham, North Carolina
Conditions: Breast Cancer